Home › Research › Treatments
Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia
Almaraz AC, Driver-Dunckley ED, Woodruff BK, Wellik KE, Caselli RJ, Demaerschalk BM, Adler CH, Caviness JN et al.. The neurologist, 2009-07-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Background Impairment of multiple neurotransmitter networks, including acetylcholine, may contribute to the cognitive impairment in patients with Parkinson disease with dementia (PDD). Therefore, cholinesterase inhibitors might improve cognitive function in PDD. On the other hand, enhancing cholinergic function could plausibly worsen features of parkinsonism. Objective To determine if oral cholinesterase inhibitors improve measures of cognitive outcome and are tolerated by people with PDD. Methods We addressed the question through the development of a critically appraised topic. Participants included consultant and resident neurologists, clinical epidemiologists, a medical librarian, and behavioral neurology and movement disorder specialists. Participants began with a structured clinical question, devised search strategies, compiled the best evidence, performed a critical appraisal, summarized the evidence, provided commentary, and declared bottom-line conclusions. Results A randomized controlled trial (n = 541) showed that, compared with placebo, rivastigmine (mean, 8.6 mg/d) significantly improved scores on 2 coprimary cognitive outcome scales in PDD, including the Alzheimer disease Cooperative Study-Clinician's Global Impression of Change. When dichotomized to evaluate clinically significant benefit (moderate or marked improvement), this outcome was not significant (risk difference = 5.3%; 95% confidence interval (CI) = -1.6 to 12.1). The number needed to treat (NNT) to avoid clinically significant worsening of cognition was 10 (95% CI = 6-28). The NNT for the combined outcome of either achieving clinically significant benefit or avoiding significant worsening was 7. The numbers needed to harm for cholinergic side effects were 9 (95% CI = 5-24) for parkinsonian symptoms and 11 (95% CI = 6-32) for rivastigmine discontinuation due to any side effect. Conclusion Rivastigmine therapy for PDD is associated with significant tradeoffs in efficacy and adverse effects. Carefully monitored trials of rivastigmine may provide meaningful benefits for a minority of PDD patients.
What this study adds
Evidence grade: High
This is a trial of 541 participants. This review of a 541-person randomized trial found that rivastigmine improved scores on two cognitive scales in people with Parkinson disease dementia, but the difference was not significant when judged by clinically meaningful benefit. Reported effect size: 5.3%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Almaraz, A. C., Driver-Dunckley, E. D., Woodruff, B. K., Wellik, K. E., Caselli, R. J., Demaerschalk, B. M., et al. (2009). Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia. The neurologist. https://doi.org/10.1097/nrl.0b013e3181a968df
Vancouver
Almaraz AC, Driver-Dunckley ED, Woodruff BK, Wellik KE, Caselli RJ, Demaerschalk BM, et al. Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia. The neurologist. 2009. doi:10.1097/nrl.0b013e3181a968df. PMID: 19590387.
BibTeX
@article{almaraz2009-19590387,
author = {Almaraz, A. C. and Driver-Dunckley, E. D. and Woodruff, B. K. and Wellik, K. E. and Caselli, R. J. and Demaerschalk, B. M. and Adler, C. H. and Caviness, J. N. and others},
title = {{Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia}},
journal = {The neurologist},
year = {2009},
doi = {10.1097/nrl.0b013e3181a968df},
pmid = {19590387},
url = {https://doi.org/10.1097/nrl.0b013e3181a968df}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results A randomized controlled trial (n = 541) showed that, compared with placebo, rivastigmine (mean, 8.6 mg/d) significantly improved scores on 2 coprimary cognitive outcome scales in PDD, including the Alzheimer disease Cooperative Study-Clinician's Global Impression of Change.
- When dichotomized to evaluate clinically significant benefit (moderate or marked improvement), this outcome was not significant (risk difference = 5.3%; 95% confidence interval (CI) = -1.6 to 12.1).
- The number needed to treat (NNT) to avoid clinically significant worsening of cognition was 10 (95% CI = 6-28).
- The NNT for the combined outcome of either achieving clinically significant benefit or avoiding significant worsening was 7.
- Conclusion Rivastigmine therapy for PDD is associated with significant tradeoffs in efficacy and adverse effects.
Why it matters
This review of a 541-person randomized trial found that rivastigmine improved scores on two cognitive scales in people with Parkinson disease dementia, but the difference was not significant when judged by clinically meaningful benefit. The authors also note that boosting cholinergic function could plausibly worsen parkinsonism.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designrandomized controlled trial
- Participants541
- Effect size5.3%
- Evidence strengthHigh
How this study scored 55/100
Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The neurologist) |
| Journal's citation record | 1 / 4 | The Neurologist: journal h-index 78 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A meta-analysis pooling many studies (from PubMed type “Meta-Analysis”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2009 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 541 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 3 / 7 | Cited 15 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.8 citations a year over 19 year(s) since 2009 |
| Impact for its field and year | 1 / 6 | Cited 0.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Dean M. Wingerchuk: h-index 71 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Mayo Clinic: institution h-index 1,606 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 19590387) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.